{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+%28Placebo+Comparator%29&page=8",
    "query": {
      "intervention": "Vehicle (Placebo Comparator)",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 1373,
    "total_pages": 138,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+%28Placebo+Comparator%29&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+%28Placebo+Comparator%29&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T09:09:55.952Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05914805",
      "title": "A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alopecia, Androgenetic"
      ],
      "interventions": [
        {
          "name": "Clascoterone 5% solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cassiopea SpA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 762,
      "start_date": "2023-08-17",
      "completion_date": "2025-07-16",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Hollywood, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Troy",
          "state": "Michigan"
        },
        {
          "city": "Warren",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05914805"
    },
    {
      "nct_id": "NCT04084483",
      "title": "A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "K-161",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Vehicle)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 238,
      "start_date": "2019-08-04",
      "completion_date": "2020-01-09",
      "has_results": true,
      "last_update_posted_date": "2023-03-15",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 4,
      "location_summary": "Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Lewiston",
          "state": "Maine"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04084483"
    },
    {
      "nct_id": "NCT06919081",
      "title": "Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Persistent Corneal Epithelial Defect",
        "Corneal Epithelial Disorders"
      ],
      "interventions": [
        {
          "name": "Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2025-08-01",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06919081"
    },
    {
      "nct_id": "NCT01774097",
      "title": "Patients With Intermittent Claudication Injected With ALDH Bright Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Artery Disease",
        "Intermittent Claudication"
      ],
      "interventions": [
        {
          "name": "ALD-301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (vehicle)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2013-06",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 9,
      "location_summary": "Stanford, California • Gainesville, Florida • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01774097"
    },
    {
      "nct_id": "NCT00873015",
      "title": "Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Subarachnoid Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Sodium nitrite",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hope Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 19,
      "start_date": "2010-04",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00873015"
    },
    {
      "nct_id": "NCT01342315",
      "title": "Topical Antifungal Treatment for Tinea Cruris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tinea Cruris"
      ],
      "interventions": [
        {
          "name": "33525",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medicis Global Service Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 483,
      "start_date": "2011-05",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 17,
      "location_summary": "Fremont, California • Los Angeles, California • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01342315"
    },
    {
      "nct_id": "NCT03452397",
      "title": "Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)",
          "type": "DRUG"
        },
        {
          "name": "1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)",
          "type": "DRUG"
        },
        {
          "name": "2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2018-02-27",
      "completion_date": "2018-04-27",
      "has_results": true,
      "last_update_posted_date": "2021-12-14",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky • Andover, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452397"
    },
    {
      "nct_id": "NCT02144155",
      "title": "Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Oxytocin: 24IU - 168 IU",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2012-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2019-12-09",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02144155"
    },
    {
      "nct_id": "NCT01502020",
      "title": "A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Actinic Keratoses"
      ],
      "interventions": [
        {
          "name": "imiquimod cream, 3.75%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Mid-Atlantic LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 410,
      "start_date": "2011-02",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2011-12-30",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01502020"
    },
    {
      "nct_id": "NCT04286789",
      "title": "Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Low dose ORTD-1",
          "type": "DRUG"
        },
        {
          "name": "Low dose vehicle control",
          "type": "DRUG"
        },
        {
          "name": "High dose ORTD-1",
          "type": "DRUG"
        },
        {
          "name": "High dose vehicle control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oryn Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2021-03-22",
      "completion_date": "2021-10-12",
      "has_results": false,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-10-09T09:09:55.952Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Tustin, California • Miami, Florida",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04286789"
    }
  ]
}